Study	Reason for exclusion
Adams 2013	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Agahi 2017	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Agarwal 2019	Allocation: randomised Participants: people with schizophrenia (with early co‐morbid diabetes or prediabetes) Interventions: not a prevention study
Assuncao 2006	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Atmaca 2003	Allocation: randomised Participants: people with schizophrenia on olanzapine monotherapy Interventions: not a prevention study
Atmaca 2004	Allocation: randomised Participants: people with schizophrenia on quetiapine monotherapy Interventions: not a prevention study
Ball 2011	Allocation: randomised Participants: people with schizophrenia treated with clozapine or olanzapine Interventions: not a prevention study
Baptista 2007	Allocation: randomised Participants: people with schizophrenia or people with bipolar disorder under olanzapine administration Interventions: not a prevention study
Baptista 2008	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
Baptista 2009	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
Barak 2010	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
Barak 2016	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
Biedermann 2014	Allocation: randomised Participants: schizophrenia outpatients Interventions: not a prevention study
Borba 2011	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Borovicka 2002	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Bushe 2010	Allocation: randomised Participants: people with schizophrenia Intervention: compared weight measures in 2 antipsychotic groups independently; not adjunctive treatment
Bustillo 2003	Allocation: randomised Participants: schizophrenia outpatients treated with olanzapine Interventions: not a prevention study
Carrizo 2009	Allocation: randomised Participants: patients under prolonged clozapine administration Interventions: not a prevention study
Chang 2012	Allocation: randomised Participants: clozapine‐treated patients with refractory schizophrenia Internvetion: not a prevention study.
Chen 2010	Allocation: randomised Participants: people with schizophrenia treated with clozapine Intervention: clozapine + metformin + behavioural lifestyle Intervention compared with clozapine only. Cannot separate metformin effects from behavioural intervention
Chen 2013	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Chen 2015	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Chiu 2016	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Correll 2009	Allocation: not randomised
Correll 2013	Allocation: not randomised
Correll 2020b	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
CTRI/2013/05/003685 2013	Allocation: randomised Participants: people with schizophrenia Intervention: metformin Outcomes: change in weight at the end of 12 weeks Other: trial was terminated due to loss to follow‐up from 22 out of 30 participants, no published data
Dai 2014	Allocation: randomised Participants: people with schizophrenia with obesity on long‐term antipsychotic treatment Interventions: not a prevention study
Danilov 2014	Allocation: unclear from methods written in abstract Participants: people with schizophrenia Interventions: not a prevention study Note: only the abstract of this study was written in English and the publication could not be translated, despite best attempts; abstract did not provide sufficient detail on randomisation methods
Deberdt 2005	Allocation: randomised Participants: people with schizophrenia with olanzapine treatment Interventions: not a prevention study
De Hert 2006	Allocation: not randomised
de Silva 2015	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder Interventions: not a prevention study
Deutsch 2003	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Ding 2005	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Egger 2007	Allocation: randomised Participants: < 50% schizophrenia‐affected sample
Eriksson 2019	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Fadai 2014	Allocation: randomised Participants: people with schizophrenia on olanzapine treatment Interventions: not a prevention study
Faghihi 2012	Allocation: randomised Participants: < 50% schizophrenia‐affected sample
Fan 2013	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Fleischhacker 2010	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Ghanizadeh 2013	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Goodall 1988	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Graham 2005	Allocation: randomised Participants: schizophrenia, schizoaffective, bipolar disorder patients that have gained weight with antipsychotics Interventions: not a prevention study
Hadley 2009	Allocation: not a randomised study, was a review article
Hebrani 2015	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Heikkinen 1993	Allocation: randomised Participants: schizophrenia Intervention: compared weight measures in 2 antipsychotic groups independently; not adjunctive treatment
Henderson 2005a	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder treated with olanzapine Interventions: not a prevention study
Henderson 2007	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder treated with clozapine Interventions: not a prevention study
Henderson 2009a	Allocation: randomised Participants: people with schizophrenia and insulin resistance treated with clozapine Interventions: not a prevention study
Henderson 2009b	Allocation: not a randomised study; cross‐over design with no proper comparator group
Henderson 2011	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Hoffmann 2012	Allocation: not a randomised study; cross‐over design with no proper comparator group
Holka‐Pokorska 2015	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
Hu 2013	Allocation: randomised Participants: people with schizophrenia treated with olanzapine Interventions: not a prevention study
IRCT20191223045870N1	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Ishoy 2017	Allocation: randomised Participants: schizophrenia spectrum patients Interventions: not a prevention study
Jamilian 2018	Allocation: randomised Participants: schizophrenia inpatient and outpatients Interventions: not a prevention study
Jarskog 2013	Allocation: randomised Participants: outpatients with chronic schizophrenia or schizoaffective disorder Interventions: not a prevention study
Jarskog 2018	Allocation: randomised Participants: overweight schizophrenia patients Interventions: not a prevention study
Jiang 2017	Allocation: randomised Participants: people with schizophrenia with metabolic syndrome Interventions: not a prevention study
Joffe 2008	Allocation: randomised Participants: overweight people with schizophrenia treated with clozapine or olanzapine Interventions: not a prevention study
Kang 2018	Allocation: randomised Participants: people with schizophrenia or bipolar disorder Interventions: not a prevention study
Kelly 2011	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder Interventions: not a prevention study
Khan 2020	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Kim 2007	Allocation: unclear from methods written in abstract Participants: people with schizophrenia Interventions: not a prevention study Note: full‐text publication could not be obtained despite best attempts to contact study authors; abstract did not provide sufficient detail on randomisation methods
Kim 2016	Allocation: randomised Participants: people with schizophrenia on atypical antipsychotics Interventions: not a prevention study
Klein 2006	Allocation: randomised Participants: < 50% schizophrenia‐affected sample
Klein 2008	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Ko 2005	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Kwon 2006	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Larsen 2017	Allocation: randomised Participants: overweight/obese people with schizophrenia‐spectrum disorder treated with clozapine or olanzapine Interventions: not a prevention study
Li 2013	Allocation: randomised Participants: schizophrenia Interventions: not a prevention study
Li 2020	Allocation: randomised Participants: schizophrenia Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS); not a pharmacological adjunctive agent
Liu 2004	Allocation: randomised Participants: people with schizophrenia Intervention: did not study adjunctive pharmacotherapy; compared weight measures in various antipsychotic groups independently
Lu 2004	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Lyu 2018	Allocation: randomised Participants: obese men with schizophrenia Interventions: not a prevention study
Maagensen 2021	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Martin 2019	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
McElroy 2012	Allocation: randomised Participants: < 50% schizophrenia‐affected sample
Mehta 2014	Allocation: randomised Intervention: people with first‐episode schizophrenia Interventions: not a prevention study
Modell 1965	Allocation: randomised Participants: obese people with schizophrenia Interventions: not a prevention study
Muscatello 2011a	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
Muscatello 2011b	Allocation: randomised Participants: people with schizophrenia treated with clozapine Interventions: not a prevention study
NCT00044187	Allocation: randomised Participants: people with schizophrenia Intervention: not a prevention review
NCT00114595	Allocation: randomised Participants: people with dyskinesia, people with schizophrenia Interventions: not a prevention study
NCT00320723	Allocation: randomised Participants: people with schizophrenia Intervention: bupropion for nicotine replacement therapy; not a weight‐prevention study
NCT00425815	Allocation: randomised Participants: people with schizophrenia Intervention: not a weight‐intervention study
NCT00512070	Allocation: randomised Participants: people with schizophrenia, schizoaffective, bipolar, obesity, metabolic syndrome Interventions: not a prevention study
NCT00672464	Allocation: randomised Particiapnts: people with schizophrenia Interventions: not a prevention study
NCT01491490	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
NCT03132571	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Peng 2016	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Pierre 2007	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder Interventions: not a prevention study
Qi 2014	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Radulovic 2002	Allcoation: randomised. Participants: people with schizophrenia Interventions: not a prevention study
Ranjbar 2013	Allocation: randomised Participants: people with schizophrenia, schizoaffective and schizophreniform disorders who received olanzapine for the first time Interventions: not a prevention study
Reeves 2013	Allocation: randomised Participants: youth who have experienced clinically significant weight gain during antipsychotic treatment Interventions: not a prevention study
Simmons 2018	Allocation: randomised Participants: people with schizophrenia, schizophreniform, bipolar I disorder. Intervention: not studying adjunctive pharmacotherapy; comparing weight gain in ALKS 3831 treatment versus olanzapine
Siskind 2018	Allocation: randomised Participants: people with schizophrenia with metabolic syndrome newly commenced on clozapine Interventions: not a prevention study
Siskind 2020	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Smith 2013	Allocation: randomised Participants: people with schizophrenia treated with antipsychotic medication Interventions: not a prevention study
Smith 2018	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Strous 2007	Allocation: randomised Participants: people with chronic schizophrenia stabilised on olanzapine Intervnetion: not a prevention study
Sulejmanpasic 2019	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Talaei 2016	Allocation: randomised Participants: patients hospitalised and treated with olanzapine due to the onset of an acute episode of schizophrenia or a manic episode of bipolar I disorder Interventions: not a prevention study
Tavakoli 2014	Allocation: randomised Participants: people with schizophrenia with metabolic syndrome Interventions: not a prevention study
Taveira 2014	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder on a stable dose of olanzapine Interventions: not a prevention study
Tek 2014	Allocation: randomised Participants: women with schizophrenia Interventions: not a prevention study
Terevnikov 2013	Allocation: randomised Participants: people with first‐generation schizophrenia treated with antipsychotics Interventions: not a prevention study
Tiihonen 2005	Allocation: randomised Participants: treatment‐resistant people with chronic schizophrenia Internventions: not a prevention study
Wang 2009	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Wang 2010	Allocation: randomised Participants: people with schizophrenia Intervention: comparing anaesthesia for electroconvulsive therapy
Wang 2012	Allocation: randomised Participants: people with first‐episode schizophrenia who gained > 7% of their weight Interventions: not a prevention study
Wang 2020a	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Wang 2020b	Allocation: randomised Participants: people with schizophrenia Intervention: topiramate and metformin were compared, but no placebo control or usual care group to use as a comparator
Weber 2006	Allocation: randomised Participants: not indicated Intervention: no pharmacological adjunct provided, added cognitive/behavioural intervention only
Weiner 2012	Allocation: randomised Participants: people with schizophrenia or schizoaffective disorder Intervention: bupropion for nicotine replacement therapy; not a weight prevention study
Whicher 2021	Allocation: randomised Participants: people with schizophrenia Interventions: not a prevention study
Wu 2012	Allocation: randomised Participants: people with first‐episode schizophrenia who gained > 7% of their pre‐drug weight Interventions: not a prevention study
Yagcioglu 2005	Allocation: randomised Participants: people with schizophrenia partially responsive to clozapine Intervention: not a weight loss intervention.
Yoon 2008	Allocation: randomised Participants: inpatients with schizophrenia Interventions: not a prevention study